Roger D. Dansey's most recent trade in Kronos Bio Inc was a trade of 68,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kronos Bio Inc | Roger D. Dansey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 68,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Roger D. Dansey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 34,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Kronos Bio Inc | Roger D. Dansey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Jun 2025 | 5,868 | 0 | - | - | Stock Option (Right to Buy) | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 2,167 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 2,167 | 8,916 (0%) | 0% | - | Common Stock | |
| Kronos Bio Inc | Roger D. Dansey | Director | 25 Jun 2024 | 34,000 | 34,000 | - | - | Stock Option (Right to Buy) | ||
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 2,917 | 2,917 | - | - | Common Stock Options | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 2,167 | 2,167 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,166 | 6,749 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,166 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 1,000 | 4,583 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 1,000 | 0 | - | - | Restricted Stock Unit | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 1,872 | 116,813 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 206.00 per share. | 28 Aug 2023 | 1,016 | 115,797 (0%) | 0% | 206 | 209,296 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 25,747 | 125,193 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale or transfer of securities back to the company at price $ 193.87 per share. | 15 Aug 2023 | 6,100 | 117,289 (0%) | 0% | 193.9 | 1,182,600 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale or transfer of securities back to the company at price $ 193.87 per share. | 15 Aug 2023 | 2,348 | 114,941 (0%) | 0% | 193.9 | 455,204 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale or transfer of securities back to the company at price $ 193.87 per share. | 15 Aug 2023 | 1,804 | 123,389 (0%) | 0% | 193.9 | 349,739 | Common Stock |
| Kronos Bio Inc | Roger D. Dansey | Director | 22 Jun 2023 | 5,868 | 5,868 | - | - | Stock Option (Right to Buy) | ||
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2023 | 35,000 | 35,000 | - | - | Common Stock Options | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2023 | 26,000 | 26,000 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2023 | 19,000 | 43,000 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2023 | 19,000 | 0 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2023 | 12,000 | 12,000 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2023 | 12,000 | 24,000 (0%) | 0% | - | Common Stock | |
| Kronos Bio Inc | Roger D. Dansey | Director | 20 Apr 2023 | 68,000 | 68,000 | - | - | Director Stock Option (Right to Buy) | ||
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 205.95 per share. | 17 Apr 2023 | 10,000 | 99,389 (0%) | 0% | 205.9 | 2,059,488 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.64 per share. | 17 Apr 2023 | 10,000 | 109,389 (0%) | 0% | 72.6 | 726,400 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2023 | 10,000 | 18,083 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 2,260 | 99,113 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 199.81 per share. | 15 Mar 2023 | 10,000 | 96,853 (0%) | 0% | 199.8 | 1,998,115 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 10,000 | 28,083 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.64 per share. | 15 Mar 2023 | 10,000 | 106,853 (0%) | 0% | 72.6 | 726,400 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 10,000 | 38,083 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.64 per share. | 15 Feb 2023 | 10,000 | 106,853 (0%) | 0% | 72.6 | 726,400 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 140.55 per share. | 15 Feb 2023 | 7,185 | 99,468 (0%) | 0% | 140.6 | 1,009,852 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 141.04 per share. | 15 Feb 2023 | 2,615 | 96,853 (0%) | 0% | 141.0 | 368,820 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 138.62 per share. | 15 Feb 2023 | 200 | 106,653 (0%) | 0% | 138.6 | 27,724 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 138.52 per share. | 02 Feb 2023 | 783 | 96,853 (0%) | 0% | 138.5 | 108,461 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2023 | 10,000 | 48,083 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 24 Jan 2023 | 10,000 | 97,539 (0%) | 0% | 135 | 1,350,000 | Common Stock |
| Seagen Inc | Roger D. Dansey | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.64 per share. | 24 Jan 2023 | 10,000 | 107,539 (0%) | 0% | 72.6 | 726,400 | Common Stock |
| Seagen Inc | Roger D. Dansey | President R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 7,500 | 58,083 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | President R&D & CMO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 04 Jan 2023 | 7,500 | 97,539 (0%) | 0% | 135 | 1,012,500 | Common Stock |
| Seagen Inc | Roger D. Dansey | President R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.64 per share. | 04 Jan 2023 | 7,500 | 105,039 (0%) | 0% | 72.6 | 544,800 | Common Stock |
| Seagen Inc | Roger D. Dansey | President R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 72.64 per share. | 04 Jan 2023 | 2,500 | 100,039 (0%) | 0% | 72.6 | 181,600 | Common Stock |
| Seagen Inc | Roger D. Dansey | President R&D & CMO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 04 Jan 2023 | 2,500 | 97,539 (0%) | 0% | 135 | 337,500 | Common Stock |
| Seagen Inc | Roger D. Dansey | President R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 2,500 | 65,583 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Nov 2022 | 275,000 | 275,000 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 4,607 | 9,403 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 17 Oct 2022 | 4,607 | 97,539 (0%) | 0% | 135 | 621,945 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.45 per share. | 17 Oct 2022 | 4,607 | 102,146 (0%) | 0% | 77.4 | 356,812 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 3,189 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 17 Oct 2022 | 3,189 | 97,539 (0%) | 0% | 135 | 430,515 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 76.86 per share. | 17 Oct 2022 | 3,189 | 100,728 (0%) | 0% | 76.9 | 245,107 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 2,204 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 135.00 per share. | 17 Oct 2022 | 2,204 | 97,539 (0%) | 0% | 135 | 297,540 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.11 per share. | 17 Oct 2022 | 2,204 | 99,743 (0%) | 0% | 65.1 | 143,502 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 154.41 per share. | 31 Aug 2022 | 4,029 | 97,539 (0%) | 0% | 154.4 | 622,136 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 154.41 per share. | 31 Aug 2022 | 806 | 101,752 (0%) | 0% | 154.4 | 124,458 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 154.41 per share. | 31 Aug 2022 | 184 | 101,568 (0%) | 0% | 154.4 | 28,412 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 44,625 | 106,812 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 170.22 per share. | 15 Aug 2022 | 2,406 | 104,406 (0%) | 0% | 170.2 | 409,538 | Common Stock |
| Seagen Inc | Roger D. Dansey | Interim CEO & CMO | Sale of securities on an exchange or to another person at price $ 170.22 per share. | 15 Aug 2022 | 1,848 | 102,558 (0%) | 0% | 170.2 | 314,558 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 17,361 | 4,587 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.11 per share. | 28 Jun 2022 | 17,361 | 94,336 (0%) | 0% | 65.1 | 1,130,375 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 28 Jun 2022 | 17,361 | 76,975 (0%) | 0% | 180 | 3,124,980 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 28 Jun 2022 | 14,891 | 62,084 (0%) | 0% | 180 | 2,680,380 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 913 | 3,674 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 28 Jun 2022 | 913 | 76,975 (0%) | 0% | 180 | 164,340 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.11 per share. | 28 Jun 2022 | 913 | 77,888 (0%) | 0% | 65.1 | 59,445 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 735 | 2,204 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2022 | 735 | 2,939 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 28 Jun 2022 | 735 | 76,975 (0%) | 0% | 180 | 132,300 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.11 per share. | 28 Jun 2022 | 735 | 77,710 (0%) | 0% | 65.1 | 47,856 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 180.00 per share. | 28 Jun 2022 | 735 | 76,975 (0%) | 0% | 180 | 132,300 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 65.11 per share. | 28 Jun 2022 | 735 | 77,710 (0%) | 0% | 65.1 | 47,856 | Common Stock |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 28,000 | 28,000 | - | - | Common Stock Options | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 19,000 | 19,000 | - | - | Restricted Stock Unit | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2022 | 12,000 | 12,000 (0%) | 0% | - | Common Stock | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2022 | 12,000 | 24,000 | - | - | Restricted Stock Unit | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 137.58 per share. | 02 Feb 2022 | 739 | 78,947 (0%) | 0% | 137.6 | 101,672 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 136.14 per share. | 02 Feb 2022 | 703 | 78,244 (0%) | 0% | 136.1 | 95,706 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 152.58 per share. | 03 Jan 2022 | 3,470 | 84,891 (0%) | 0% | 152.6 | 529,459 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 152.58 per share. | 03 Jan 2022 | 3,470 | 81,421 (0%) | 0% | 152.6 | 529,459 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 152.58 per share. | 03 Jan 2022 | 1,735 | 79,686 (0%) | 0% | 152.6 | 264,730 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 155.58 per share. | 20 Dec 2021 | 280 | 88,361 (0%) | 0% | 155.6 | 43,562 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 149.85 per share. | 20 Dec 2021 | 280 | 88,641 (0%) | 0% | 149.9 | 41,958 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 166.22 per share. | 23 Sep 2021 | 3,453 | 88,921 (0%) | 0% | 166.2 | 573,958 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 166.22 per share. | 23 Sep 2021 | 129 | 85,468 (0%) | 0% | 166.2 | 21,442 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 167.52 per share. | 31 Aug 2021 | 3,701 | 86,249 (0%) | 0% | 167.5 | 619,975 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 167.52 per share. | 31 Aug 2021 | 741 | 85,508 (0%) | 0% | 167.5 | 124,129 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 167.51 per share. | 31 Aug 2021 | 169 | 85,339 (0%) | 0% | 167.5 | 28,310 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 41,250 | 41,250 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 17,172 | 89,950 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 154.55 per share. | 16 Aug 2021 | 1,657 | 72,778 (0%) | 0% | 154.6 | 256,096 | Common Stock |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 642 | 642 | - | - | Incentive Stock Option (right to buy) | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 152.22 per share. | 16 Jun 2021 | 25,109 | 84,435 (0%) | 0% | 152.2 | 3,822,034 | Common Stock |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 54,000 | 54,000 | - | - | Common Stock Options | |
| Inovio Pharmaceuticals Inc | Roger D. Dansey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2021 | 36,000 | 36,000 | - | - | Restricted Stock Unit | |
| Seagen Inc | Roger D. Dansey | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 163.97 per share. | 02 Feb 2021 | 728 | 109,544 (0%) | 0% | 164.0 | 119,370 | Common Stock |